NBY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NBY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-03-28), NovaBay Pharmaceuticals's Intrinsic Value: Projected FCF is $-12.07. The stock price of NovaBay Pharmaceuticals is $0.104698. Therefore, NovaBay Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for NovaBay Pharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:
The historical data trend for NovaBay Pharmaceuticals's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NovaBay Pharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where NovaBay Pharmaceuticals's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get NovaBay Pharmaceuticals's Free Cash Flow(6 year avg) = $-6.54.
NovaBay Pharmaceuticals's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Sep23) | * | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (9.5203515959648 | * | -6.53744 | + | 7.037 | * | 0.8) | / | 4.692 | |
= | -12.07 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovaBay Pharmaceuticals (AMEX:NBY) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
NovaBay Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 0.104698 | / | -12.065031401859 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Tommy Law | officer: Interim CFO | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Jeffrey Kunin | officer: President, DERMAdoctor, LLC | 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150 |
Audrey Kunin | officer: Chief Product Officer | 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150 |
Justin Hall | officer: General Counsel | 5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608 |
Yongxiang Zheng | director | NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316 |
Julie Garlikov | director | 2420 17TH STREET, SUITE 220, DENVER CO 80202 |
Andrew D. Jones | officer: CFO and Treasurer | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Mijia Wu | director | SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA |
Jian Ping Fu | 10 percent owner | LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125 |
Wang Xu | officer: NEO - Sr Mgr and Controller | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Swan Sit | director | 95 JACKSON STREET, NEWTON MA 02459 |
Yenyou Zheng | director | 1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9 |
Xiaopei Wang | director | 2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109 |
Jason Philip Raleigh | officer: Interim CFO and Treasurer | 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608 |
Pioneer Pharma (hong Kong) Co Ltd | 10 percent owner | FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000 |
From GuruFocus
By PRNewswire 04-20-2020
By PRNewswire 07-13-2020
By PRNewswire 05-14-2020
By PRNewswire 05-15-2019
By Marketwired 08-09-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.